Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZEN003365 in Relapsed/Refractory LPM or AML
NCT02238522Phase 1Withdrawn
- Sponsor
- Zenith Epigenetics
- Start
- Oct 2014
- Primary completion
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ZEN-3365 in lymphoproliferative disorder (LPD) and acute myeloid leukemia (AML) (2 arms), sponsored by Zenith Epigenetics. Primary endpoints: Frequency of adverse events at 12 weeks, Dose Limiting Toxicities at 25 days and 3 more. Planned start Oct 2014; status: withdrawn.
02
Drugs
ZEN-3365
03
Conditions
lymphoproliferative disorder (LPD)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02238522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02238522.